Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRIDENT Cognitive Sub-Study
NCT03785067Phase 3Terminated
- Sponsor
- The George Institute for Global Health
- Start
- Feb 2020
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of telmisartan, amlodipine and indapamide in No canonical disease name; "cognitive deterioration" is a descriptive term, not a recognized disease entity, Dementia and hypertension (HTN) (2 arms), sponsored by The George Institute for Global Health. Primary endpoint: Cambridge Neuropsychological Test Automated Battery Paired Associates Learning at 36 months. Started Feb 2020; status: terminated.
02
Drugs
telmisartanamlodipineindapamide
03
Conditions
No canonical disease name; "cognitive deterioration" is a descriptive term, not a recognized disease entity.Dementiahypertension (HTN)
Beyond the preview
Go deeper on NCT03785067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03785067.